Pedigo N W
Department of Pharmacology, University of Kentucky A.B. Chandler Medical Center, Lexington 40536-0216.
Life Sci. 1994;55(25-26):1985-91. doi: 10.1016/0024-3205(94)00378-5.
Neurotransmitter receptor plasticity is an important part of the compensatory processes by which the central nervous system adapts to pathological insult, long-term exposure to drugs or neuronal loss with advanced age. Receptor plasticity can be manifest as changes in the number of receptors (i.e., up- or down-regulation), changes in expression of mRNA for discrete receptor proteins, or alterations in receptor coupling to signal transduction systems. Evidence exists for impaired plasticity of neurons in the aged brain, which results in decreased ability to adjust to changes in their environment. However, such data are highly dependent on the neurotransmitter examined, the stimulus for receptor regulation and the animal model chosen for study. For example, senescent rats show an age-related impairment of muscarinic receptor up- or down-regulation after long-term exposure to cholinergic drugs. Thus, young rats exposed to chronic (three weeks) intracerebroventricular infusions of methylatropine or oxotremorine exhibit compensatory changes in the density of muscarinic receptors in frontal cortex and hypothalamus. In contrast, 3H-QNB binding is unaltered in the same brain regions of identically treated senescent rats. Similar observations of impaired muscarinic receptor plasticity in senescent animals have been confirmed by other investigators. Age-related differences in coupling of brain muscarinic receptors to G-proteins and in muscarinic receptor-stimulated phosphoinositide hydrolysis have also been reported. Interestingly, neuropeptides such as neurotensin, cholecystokinin and VIP can potentiate carbachol-stimulated phosphoinositide hydrolysis in frontal cortex of both young and aged rats. This adds another level at which cholinergic neurotransmission may be modulated in senescent animals. Potential age-related differences in the effects of chronic drug treatments or experimental brain lesions on muscarinic receptor coupling to second messenger systems or on expression of mRNA for particular muscarinic receptors are currently unknown. Hence, it is possible that senescent animals may show additional deficiencies in plasticity of muscarinic receptor mediated signal transduction or expression of muscarinic receptors subtypes.
神经递质受体可塑性是中枢神经系统适应病理损伤、长期接触药物或随着年龄增长神经元丢失的代偿过程的重要组成部分。受体可塑性可表现为受体数量的变化(即上调或下调)、离散受体蛋白mRNA表达的变化,或受体与信号转导系统偶联的改变。有证据表明,衰老大脑中的神经元可塑性受损,这导致其适应环境变化的能力下降。然而,这些数据高度依赖于所研究的神经递质、受体调节的刺激因素以及所选择的用于研究的动物模型。例如,衰老大鼠在长期接触胆碱能药物后,毒蕈碱受体上调或下调存在与年龄相关的损伤。因此,长期(三周)脑室内注入甲基阿托品或氧化震颤素的幼鼠,额叶皮质和下丘脑中毒蕈碱受体密度会出现代偿性变化。相比之下,同样处理的衰老大鼠相同脑区中3H-QNB结合未发生改变。其他研究者也证实了衰老动物中毒蕈碱受体可塑性受损的类似观察结果。也有报道称,大脑毒蕈碱受体与G蛋白偶联以及毒蕈碱受体刺激的磷酸肌醇水解存在与年龄相关的差异。有趣的是,神经降压素、胆囊收缩素和血管活性肠肽等神经肽可增强年轻和衰老大鼠额叶皮质中卡巴胆碱刺激的磷酸肌醇水解。这为衰老动物中胆碱能神经传递的调节增加了另一个层面。目前尚不清楚慢性药物治疗或实验性脑损伤对毒蕈碱受体与第二信使系统偶联或特定毒蕈碱受体mRNA表达的影响中潜在的与年龄相关的差异。因此,衰老动物可能在毒蕈碱受体介导的信号转导可塑性或毒蕈碱受体亚型表达方面表现出额外的缺陷。